Documents
Application Sponsors
NDA 215973 | GILEAD SCIENCES | |
Marketing Status
Application Products
001 | INJECTABLE;INJECTION | 300MG | 0 | SUNLENCA | LENACAPAVIR |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2022-12-22 | PRIORITY |
Submissions Property Types
CDER Filings
GILEAD SCIENCES
cder:Array
(
[0] => Array
(
[ApplNo] => 215973
[companyName] => GILEAD SCIENCES
[docInserts] => ["",""]
[products] => [{"drugName":"SUNLENCA","activeIngredients":"LENACAPAVIR","strength":"300MG","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"12\/22\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215973s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"12\/22\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215973s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/215973Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2022-12-22
)
)